The use of zofenopril in myocardial infarction Review article
Article Sidebar
Published:
Mar 31, 2015
Keywords:
acute coronary syndrome, myocardial infarction, angiotensin converting enzyme inhibitor, mortality
Main Article Content
Abstract
Angiotensin converting enzyme inhibitors (ACEI) play a key role in therapy of cardiovascular diseases including patients with acute coronary syndromes. One of the most interesting ACEI due to high lipophilicity and pleiotropic activity is zofenopril. In this article, we present the current state of knowledge regarding the use of zofenopril in myocardial infarction concerning the guidelines of European Society of Cardiology.
Article Details
How to Cite
Rosiak , M., Postuła , M., & Kosior , D. A. (2015). The use of zofenopril in myocardial infarction. Medycyna Faktow (J EBM), 8(1(26), 65-69. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2326
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Nicholls M.G., Robertson J.I., Inagami T.: The renin-angiotensin system in the twenty-first century. Blood Pressure 2001; 10(5-6): 327-343.
2. Steg P.G., James S.K., Atar D. et al.: ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal 2012; 33(20): 2569-2619.
3. Hamm C.W., Bassand J.P., Agewall S. et al.: ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal 2011; 32(23): 2999-3054.
4. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995; 345(8951): 669-685.
5. Pfeffer M.A., Braunwald E., Moye L.A. et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. The New England Journal of Medicine 1992; 327(10): 669-677.
6. Torp-Pedersen C., Kober L.: Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999; 354(9172): 9-12.
7. Tio R.A., de Langen C.D., de Graeff P.A. et al.: The effects of oral pretreatment with zofenopril, an angiotensin-converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1990; 4(3): 695-703.
8. Pinto Y.M., van Wijngaarden J., van Gilst W.H. et al.: The effects of short- and long-term treatment with an ACE-inhibitor in rats with myocardial infarction. Basic Research in Cardiology 1991; 86(Suppl. 1): 165-172.
9. van Wijngaarden J., Pinto Y.M., van Gilst W.H. et al.: Converting enzyme inhibition after experimental myocardial infarction in rats: comparative study between spirapril and zofenopril. Cardiovascular Research 1991; 25(11): 936-942.
10. Ambrosioni E., Borghi C., Magnani B.: Early treatment of acute myocardial infarction with angiotensin-converting enzyme inhibition: safety considerations. SMILE pilot study working party. The American Journal of Cardiology 1991; 68(14): 101D-10D.
11. Ambrosioni E., Borghi C., Magnani B.: The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The New England Journal of Medicine 1995; 332(2): 80-85.
12. Borghi C., Ambrosioni E., Magnani B.: Effects of the early administration of zofenopril on onset and progression of congestive heart failure in patients with anterior wall acute myocardial infarction. The SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. The American Journal of Cardiology 1996; 78(3): 317-322.
13. Borghi C., Bacchelli S., Esposti D.D. et al.: Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction. Diabetes Care 2003; 26(6): 1862-1868.
14. Borghi C., Ambrosioni E.: Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. American Heart Journal 2003; 145(1): 80-87.
15. Borghi C., Ambrosioni E.: Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. American Heart Journal 2007; 153(3): 445 e7-e14.
16. Jhund P., McMurray J.J.: Does aspirin reduce the benefit of an angiotensin-converting enzyme inhibitor? Choosing between the Scylla of observational studies and the Charybdis of subgroup analysis. Circulation 2006; 113(22): 2566-2568.
17. Borghi C., Ambrosioni E., Novo S. et al.: Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4). Clinical Cardiology 2012; 35(7): 416-423.
18. Borghi C., Ambrosioni E., Omboni S. et al.: Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study. Journal of Hypertension 2013; 31(6): 1256-1264.
2. Steg P.G., James S.K., Atar D. et al.: ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal 2012; 33(20): 2569-2619.
3. Hamm C.W., Bassand J.P., Agewall S. et al.: ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal 2011; 32(23): 2999-3054.
4. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995; 345(8951): 669-685.
5. Pfeffer M.A., Braunwald E., Moye L.A. et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. The New England Journal of Medicine 1992; 327(10): 669-677.
6. Torp-Pedersen C., Kober L.: Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999; 354(9172): 9-12.
7. Tio R.A., de Langen C.D., de Graeff P.A. et al.: The effects of oral pretreatment with zofenopril, an angiotensin-converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1990; 4(3): 695-703.
8. Pinto Y.M., van Wijngaarden J., van Gilst W.H. et al.: The effects of short- and long-term treatment with an ACE-inhibitor in rats with myocardial infarction. Basic Research in Cardiology 1991; 86(Suppl. 1): 165-172.
9. van Wijngaarden J., Pinto Y.M., van Gilst W.H. et al.: Converting enzyme inhibition after experimental myocardial infarction in rats: comparative study between spirapril and zofenopril. Cardiovascular Research 1991; 25(11): 936-942.
10. Ambrosioni E., Borghi C., Magnani B.: Early treatment of acute myocardial infarction with angiotensin-converting enzyme inhibition: safety considerations. SMILE pilot study working party. The American Journal of Cardiology 1991; 68(14): 101D-10D.
11. Ambrosioni E., Borghi C., Magnani B.: The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The New England Journal of Medicine 1995; 332(2): 80-85.
12. Borghi C., Ambrosioni E., Magnani B.: Effects of the early administration of zofenopril on onset and progression of congestive heart failure in patients with anterior wall acute myocardial infarction. The SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. The American Journal of Cardiology 1996; 78(3): 317-322.
13. Borghi C., Bacchelli S., Esposti D.D. et al.: Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction. Diabetes Care 2003; 26(6): 1862-1868.
14. Borghi C., Ambrosioni E.: Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. American Heart Journal 2003; 145(1): 80-87.
15. Borghi C., Ambrosioni E.: Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. American Heart Journal 2007; 153(3): 445 e7-e14.
16. Jhund P., McMurray J.J.: Does aspirin reduce the benefit of an angiotensin-converting enzyme inhibitor? Choosing between the Scylla of observational studies and the Charybdis of subgroup analysis. Circulation 2006; 113(22): 2566-2568.
17. Borghi C., Ambrosioni E., Novo S. et al.: Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4). Clinical Cardiology 2012; 35(7): 416-423.
18. Borghi C., Ambrosioni E., Omboni S. et al.: Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study. Journal of Hypertension 2013; 31(6): 1256-1264.